Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia

Area of Science:

• Hematology
• Molecular Biology
• Genomics

Background:

• Acute myeloid leukemia (AML) treatment can be enhanced by combining novel therapeutics with all-trans-retinoic acid (ATRA).
• Understanding the molecular mechanisms of ATRA-induced differentiation is crucial for developing more effective AML therapies.

Purpose of the Study:

• To identify key molecular targets for enhancing ATRA efficacy in AML treatment.
• To analyze the transcriptomic response of different AML cell lines to ATRA exposure over time.

Main Methods:

• Genome-scale transcriptome analysis of HL-60, NB4, and K562 cells treated with ATRA.
• Hierarchical modeling of transcriptomic data to identify key regulatory genes.
• Proteome-level analysis using TMT-based mass-spectrometry to validate gene expression changes.

Main Results:

• Identified differentially expressed genes (DEGs) in response to ATRA across cell lines and time points.
• Determined cyclin-dependent kinase 6 (CDK6), tumor necrosis factor alpha (TNF-alpha), and CUX1 as key regulators.
• Observed down-regulation of CDK6 at both transcriptome and proteome levels after prolonged ATRA treatment.

Conclusions:

• CDK6 is a key regulator in ATRA-treated AML cells.
• Combining ATRA (tretinoin) with a CDK6 inhibitor (palbociclib) presents a potential alternative therapeutic strategy for AML.